Request Demo
Last update 27 Feb 2026
Povidone-Iodine
Last update 27 Feb 2026
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Povidone Iodine, Povidone-iodine (JP17/USP), 原位凝胶缓释滴眼液 + [12] |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Japan (01 Nov 1965), |
RegulationOrphan Drug (United States) |
Login to view timeline
Structure/Sequence
Molecular FormulaC6H9I2NO |
InChIKeyCPKVUHPKYQGHMW-UHFFFAOYSA-N |
CAS Registry25655-41-8 |
Related
335
Clinical Trials associated with Povidone-IodineNCT04200729
Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis
NCT06463678
A Phase II, Multi-center, Randomized, Masked, Parallel-Control Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% PVP-Iodine) Gel Forming Ophthalmic Solution in the Treatment of Fungal Keratitis
ACTRN12626000076370
Trial for Reducing Infection After Arthroplasty with Dilute Povidone-Iodine in end-stage arthritis patients, with the primary outcome being a validated diagnosis of surgical site infection (SSI) at 3 months post-surgery.
100 Clinical Results associated with Povidone-Iodine
Login to view more data
100 Translational Medicine associated with Povidone-Iodine
Login to view more data
100 Patents (Medical) associated with Povidone-Iodine
Login to view more data
4,295
Literatures (Medical) associated with Povidone-Iodine01 Jun 2026Public health in practice (Oxford, England)
Universal decolonization for methicillin-resistant Staphylococcus aureus and carbapenem-resistant Acinetobacter in elderly homes: A large cohort of over 16,000 residents in Hong Kong
Article
Author: Chow, Vincent ; Liu, Andrea ; Luk, Kristine ; Chuang, Vivien Wai-Man ; Lai, Raymond Wai-Man ; Chen, Hong ; Tsui, Edwin Lok-Kin ; Cheng, Vincent Chi-Chung ; Ma, Edmond Siu-Keung ; Lee, Suet-Yi ; Lung, David Christopher ; Wong, Shuk-Ching ; Yuen, Kwok-Yung ; Hsu, Enoch
Background:
We conducted a decolonization program for methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Acinetobacter (CRA) among residential care homes for the elderly (RCHE) residents by providing universal decolonization using nasal povidone-iodine and chlorhexidine baths at the RCHEs and during hospitalization.
Objectives:
1. To investigate the effectiveness of decolonization of MRSA and CRA in elderly homes. 2. To assess the incidence of MRSA and CRA infections bacteremia, associated morbidity and mortality in elderly homes. 3. To investigate MRSA infection reduction and risk ratio amongst the elderly residents.
Study design:
This quality improvement program adopted a quasi-experimental design.
Methods:
A total of 20,741 RCHE residents were instructed to apply 10 % povidone-iodine nasal ointment once daily, Monday to Friday, every alternate week, while 2 % chlorhexidine gluconate solution was used for bathing on alternate days. Group 1 included RCHE residents who underwent decolonization at the RCHEs and during hospitalization, whereas Group 2 received decolonization at the RCHEs only. The residents who stayed in the RCHEs other than the 330 invited residents RCHEs were considered the control group when they admitted to their network hospitals. We compared the incidence of any MRSA and CRA infections, bacteremia, and associated death in 2023 with the rates during the baseline period from 2017 to 2019, using Poisson exact test.
Results:
A total of 257/330 (77.9 %) RCHEs continued the program, involving 16,190 residents. The mean utilization of povidone-iodine ranged from 79.4 % to 96.2 %, whereas chlorhexidine utilization ranged from 79.9 % to 97.2 %. MRSA infection was reduced in Group 1 with a risk ratio of 0.878 (95 %CI: 0.776-0.992, p = 0.035) compared with that at baseline. For bacteremia, larger reductions were noted in Group 1 and Group 2, with risk ratios of 0.719 (95 %CI: 0.448-1.115, p = 0.158) and 0.721 (95 %CI: 0.418-1.192, p = 0.207), respectively, compared to the control 0.785 (95 %CI: 0.621-0.984, p = 0.036). Regarding mortality associated with MRSA, a differential reduction of 51.1 %, 18.7 % and 22.2 % were observed for Group 1, Group 2 and the control respectively. For CRA, no statistically significant reduction was detected in the intervention groups for infection, bacteremia or death.
Conclusions:
We demonstrated a reduction in hospital admissions due to MRSA infections following the decolonization program for residents in RCHEs and during hospitalization.
01 Mar 2026JOURNAL OF PHARMACEUTICAL SCIENCES
A comprehensive discussion on analytical method development and validation of a USP type-IV dissolution method for dexamethasone in a combination ophthalmic suspension with povidone-iodine
Article
Author: Mandal, Likhit ; Vemuri, Dr Praveen Kumar
Antimicrobial resistance resulting from the widespread use of topical antibiotics has accelerated the need for non-antibiotic strategies in ocular therapy. Povidone-iodine (PVP-I) offers broad antimicrobial activity without inducing resistance, while dexamethasone provides potent anti-inflammatory effects, making their combination a promising ophthalmic suspension for infectious and inflammatory conditions. To ensure therapeutic consistency, in-vitro dissolution testing is critical for suspension of Dexamethasone, as it characterizes drug release, supports formulation optimization, and provides evidence for regulatory bio-waivers. This investigation was carried out to develop and validate a USP Type-IV flow-through cell method (closed-loop configuration) for assessing the in-vitro release behavior of dexamethasone (0.1%) from povidone-iodine (0.6%) and dexamethasone (0.1%) ophthalmic suspension. The current dissolution method employed phosphate buffer (pH 7.4) with 0.1% β-cyclodextrin as medium, chosen for solubility, stability, and sink condition. A 100 kDa cellulose ester membrane enabled controlled diffusion. Chromatographic separation was performed on an ACE Excel-5 C8 column (250 × 4.6 mm, 5 µm) using an isocratic mobile phase of 0.6% β-cyclodextrin in water and acetonitrile (1:1 v/v). Partial validation per ICH Q2(R2) confirmed excellent linearity (r² > 0.999), precision (%RSD < 2.0), accuracy (98.5-101.5%), and solution stability for 72 h. The method was discriminatory for formulation changes and suitable for routine and stability testing of ophthalmic suspensions.
01 Mar 2026JSES international
Subcutaneous tissue disinfection is more effective than the use of electrocautery in reducing Cutibacterium acnes burden in open shoulder surgery
Article
Author: Moor, Beat Kaspar ; Léger, Bertrand ; Passaplan, Caroline ; Gallusser, Nicolas ; Emonet, Stéphane
Background:
Cutibacterium acnes (C. acnes) is a pathogen linked to infections following shoulder surgery. Exposure can occur during surgical dissection and spread in the surgical field through the surgeon's gloves and instruments. Disinfection of the subcutaneous tissue has been shown to reduce its contamination. No evidence has been provided for a decrease in the transmission rate when the dissection is performed with an electrocautery. The aim of this study was to ascertain whether disinfection of subcutaneous tissue can reduce the C. acnes rate in primary open shoulder surgery in comparison with dissection performed with electrocautery. We also wanted to compare the contamination rate of the operating field after electrocautery dissection with those found in the literature.
Methods:
All patients who qualified for primary open shoulder surgery via a deltopectoral approach were prospectively included in our single-blinded, two-arm randomized clinical trial. For every patient, a skin swab from the surgical area was taken before the standard preparation of the skin. In the disinfection group, the subcutaneous layer was treated with povidone iodine solution after exposure of the deltoid fascia. The cautery group underwent subcutaneous tissue dissection using an electrocautery. After fully exposing the proximal humerus, 5 swabs were collected from various locations for microbiological analysis, following a rigorous protocol. All cultures were incubated for 14 days under both aerobic and anaerobic conditions.
Results:
Between February 2020 and July 2021, 210 shoulders were enrolled in 2 groups (140 disinfection vs. 70 cautery). The 2 groups showed no significant differences in terms of sex, age, body mass index, or diabetes prevalence. The subcutaneous disinfection protocol led to a significant decrease in the overall positive culture rate of the operating field for all bacteria (P = .001) and specifically for C. acnes (P = .021). The reduction of positive swabs for C. acnes was significant for both the surgeon's gloves (P = .004) and for the subcutaneous tissue (P = .009). C. acnes contamination rate was noted in 26% of patients in the electrocautery group and 13% in the disinfection group after exclusion of the outside scalpel blade sample, which was removed from the scrub nurse's instrument table and therefore no longer used during the procedure.
Conclusion:
Disinfection of the subcutaneous tissue reduces the contamination rate of C. acnes by a factor of 2 during open shoulder surgery compared with an approach performed with electrocautery and could limit the contamination of the operating field.
18
News (Medical) associated with Povidone-Iodine
100 Deals associated with Povidone-Iodine
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Pressure Ulcer | Japan | 01 Jul 1999 | |
| Skin Ulcer | Japan | 01 Jul 1999 | |
| Bacterial Infections and Mycoses | Australia | 07 Sep 1991 | |
| Burn infections | Australia | 07 Sep 1991 | |
| Chronic pharyngitis | Australia | 07 Sep 1991 | |
| Eye Diseases | United States | 17 Dec 1986 | |
| Disinfectants | Japan | - | 01 Nov 1965 |
| Burns | China | - | |
| Candidiasis, Vulvovaginal | China | - | |
| Hemorrhoids | China | - | |
| Skin Diseases, Infectious | China | - |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dental Plaque | Phase 3 | United States | 01 Oct 2007 | |
| Fungal keratitis | Phase 2 | - | 01 Aug 2026 | |
| Adenoviral Conjunctivitis | Phase 2 | India | 20 Feb 2023 | |
| Adenoviridae Infections | Phase 2 | India | 20 Feb 2023 | |
| acute bacterial conjunctivitis | Phase 2 | China | 05 Jan 2023 | |
| acute bacterial conjunctivitis | Phase 2 | China | 05 Jan 2023 | |
| Acute adenoviral follicular conjunctivitis | Phase 2 | China | 04 Jan 2022 | |
| Acute adenoviral follicular conjunctivitis | Phase 2 | China | 04 Jan 2022 | |
| Conjunctivitis | Phase 2 | United States | - | |
| COVID-19 | Preclinical | United States | 17 Sep 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 2,129 | (Povidone Iodine and Vancomycin Powder) | fylrkszbpj = tioevrfkmx vwosarhglr (ppzgfbktur, olywhalwsl - wherxqcoiq) View more | - | 17 Feb 2026 | ||
(Povidone Iodine Alone) | fylrkszbpj = fzxfpfxxdd vwosarhglr (ppzgfbktur, lywzvmerdi - ifrflkvboy) View more | ||||||
Phase 4 | 469 | epfhpcgwez(hkzipyybsj) = bbsrzwqihg ffnupkhvsx (vbdejguzkf ) | Positive | 04 Feb 2026 | |||
Phase 4 | 2,272 | 2% alcohol-based chlorhexidine | arqiscatox(tdqlnjyrzz) = eylpvzyklx tpyoquqbrr (fhedqheycr ) View more | Negative | 01 Jan 2026 | ||
arqiscatox(tdqlnjyrzz) = fqsskppotf tpyoquqbrr (fhedqheycr ) View more | |||||||
Phase 2 | 129 | (IVIEW-1201) | kbfkuetmih: P-Value = 0.0137 | - | 15 Jun 2025 | ||
(Ofloxacin Eye Drops) | |||||||
Phase 4 | 192 | (Treatment) | fojusojjvr(xpjtngdyie) = bkswwjoxhn vzrojasdcv (cheoopycxo, dndvorjpkr - jnqvsvjvps) View more | - | 13 Nov 2024 | ||
0.9% NaCl Solution (Placebo) | fojusojjvr(xpjtngdyie) = tqpoyamuhn vzrojasdcv (cheoopycxo, ytkkircvrd - vnfrldwske) View more | ||||||
Not Applicable | 190 | brpxntwepl(wajieejsiq) = There were no significant complications such as ARDS in any patient zcsrsvrjbv (wvpdscyfhz ) View more | Positive | 07 Sep 2024 | |||
(Pleurodesis during pleuroscopy) | |||||||
Phase 2 | 129 | jnoumgvbsb(poimrxonbw) = tncxsymrqr ewqfkkbwzj (qhnnmonepm ) | Similar | 07 May 2024 | |||
jnoumgvbsb(poimrxonbw) = uebxsgzdoy ewqfkkbwzj (qhnnmonepm ) | |||||||
Not Applicable | - | Rectal betadine preparation | wzucenbkdt(fzuscjqmmm) = kvnbflhpcr wwkiutkgum (sgpknfywqx ) View more | - | 01 May 2024 | ||
Phase 2 | 128 | 27% Ethanol plus essential oils (27% Ethanol Plus Essential Oils) | rlvqagziud(nevfxwvwgc) = mkzbpgedjd yeaexqikhe (ajdstdvkkv, 34132.53) View more | - | 25 Mar 2024 | ||
0.075% Cetylpyridinium Chloride (0.075% Cetylpyridinium Chloride) | rlvqagziud(nevfxwvwgc) = uyinnwtekt yeaexqikhe (ajdstdvkkv, 8311.31) View more | ||||||
Phase 4 | 65 | ewtacmiuji = nrpqvnnanc gabwxtquez (xuynpxsqfd, rpakrvtrui - mlkwwukolc) View more | - | 28 Jun 2023 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free